论文部分内容阅读
62例初发T2DM患者分为甘精胰岛素联合口服瑞格列奈治疗组和门冬胰岛素30治疗组,治疗12周。结果治疗后两组者的FPG、2hPG、空腹C肽、HbA1c较治疗前均显著改善(P<0.01 or 0.05),但两组间比较差异无明显统计学意义(P>0.05);依从率甘精胰岛素组高于门冬胰岛素30组(P<0.01);低血糖发生率甘精胰岛素组低于门冬胰岛素30组(P<0.05)。结论甘精胰岛素联合瑞格列奈可有效降低初发2型糖尿病患者血糖,达标率高,依从性好,低血糖发生少。
62 cases of newly diagnosed T2DM patients were divided into glargine and oral repaglinide treatment group and aspart insulin 30 treatment group for 12 weeks. Results After treatment, FPG, 2hPG, fasting C-peptide and HbA1c in both groups were significantly improved (P <0.01 or 0.05), but no significant difference was found between the two groups (P> 0.05) Insulin group was higher than insulin aspart 30 (P <0.01). The incidence of hypoglycemia was lower in insulin glargine group than in insulin 30 group (P <0.05). Conclusion Glargine and repaglinide can effectively reduce blood glucose in newly diagnosed type 2 diabetic patients with high compliance, good compliance and few hypoglycemia.